Forth Photonics

Seno Medical is a medical imaging company. It develops and markets optoacoustic imaging technology for cancer diagnosis. It offers Imagio, a breast imaging system that combines laser optics and ultrasound technology to provide fused functional and anatomical breast imaging in real-time. It was founded in 2005 and is based in San Antonio, Texas.

Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

FMI Medical Systems is developing ultra high resolution PET/CT/SPECT diagnostic imaging systems combined with drugs and molecular tracers for earliest detection and monitoring of Alzheimer's, neurodegenerative disorders, and head and neck cancers and breast cancer.

Third Eye Diagnostics is a company focused on the development of non-invasive technologies for the evaluation of intracranial pressure, operating in the medical technology sector. The company's main product is a non-invasive intracranial pressure monitor that gathers information from the patient's eye, providing a single point reading of intracranial pressure, which can be used for diagnosing and monitoring conditions like traumatic brain injuries, stroke, and glaucoma. The company primarily sells to sectors such as hospital Neuro-ICUs, emergency rooms, surgical suites, medical transport vehicles, general practitioner offices, and sports events. It is based in Bethlehem, Pennsylvania.

CardioDynamics was incorporated in 1993 and is committed to fundamentally changing drug management with ICG. The Company's primary product, the BioZ, uses proprietary Impedance Cardiography (ICG) technology to noninvasively assess a patient's hemodynamics, data which typically has been unavailable in the physician's office and available on a limited basis in the hospital only through a time-consuming, costly, and potentially dangerous invasive procedure called Pulmonary Artery Catheterization (PAC), or the Swan Ganz Catheter. Since the BioZ's ICG monitoring is noninvasive, it can be performed in outpatient areas such as physician offices, which have never before had access to hemodynamic information in treating heart failure, high blood pressure, pacemaker, and dialysis patients. In physician offices, BioZ monitoring can decrease long term costs of hypertension management through the use of appropriate drug therapies. The reduction of blood pressure results in a decrease of more costly cardiovascular conditions including heart failure, strokes, and heart attacks. In hospitals, BioZ monitoring on surgical or intensive care patients can decrease costs through the elimination of procedure risk, reduction of hospital stay, and minimization of hospital expenditures and personnel. BioZ monitoring can also provide valuable hemodynamic information in hospital areas where previously it has not been available, such as emergency departments, critical care, step-down units, and dialysis. In this new era of cost containment, healthcare payors and providers are demanding greater efficiency and cost-effectiveness without diminishing the quality of care. The BioZ's ICG monitoring systems provide a solution to meet this growing demand.